| Literature DB >> 25007902 |
Abstract
Cancer is a highly thrombophilic entity leading to a high rate of symptomatic and even asymptomatic venous thromboembolic (VTE) events in patients suffering from malignant disease. As VTE events have impact on survival and can be reduced significantly by anticoagulant treatment, guidelines on prophylaxis of these events by means of anticoagulation exist from various societies. Purpose of this review is to give a concise overview of current possibilities for prophylaxis and also for the therapy of VTE events in cancer patients.Entities:
Keywords: Cancer; low molecular weight heparin; pulmonary embolism; venous thromboembolism
Mesh:
Substances:
Year: 2014 PMID: 25007902 DOI: 10.1024/0301-1526/a000359
Source DB: PubMed Journal: Vasa ISSN: 0301-1526 Impact factor: 1.961